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ABSTRACT
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent 
lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing 
a more aggressive clinical behavior. Little is known about these cases on the 
molecular level. Therefore, the aim of the present study was to characterize DLBCL 
transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed 
an inflammatory signature pinpointing to a specific host response. In a coculture 
model resembling this host response, DEV tumor cells showed an impaired growth 
behavior. Mechanisms involved in the reduced tumor cell proliferation included 
a downregulation of MYC and its target genes. Lack of MYC expression was also 
confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 
was upregulated in DEV tumor cells after coculture with T cells or monocytes and its 
expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new 
insights into the pathogenesis of LP-DLBCL and an explanation for the relatively low 
tumor cell content. Moreover, the findings suggest that treatment of these patients 
with immune checkpoint inhibitors may enhance an already ongoing host response 
in these patients.
INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is the most 
frequent type of aggressive B cell lymphoma and comprises 
a heterogeneous mixture of cases [1]. DLBCL can be 
subdivided according to its cell of origin into germinal 
center B cell (GCB)-like and activated B cell (ABC)-like 
lymphomas [2, 3]. Assignment to GCB and ABC categories 
has also been associated with prognosis [3]. Currently, new 
treatment options for ABC-DLBCL are evolving, since 
these lymphomas are dependent on chronic active B cell 
receptor signaling and frequently engage self-antigens 
[4]. Some immunohistochemical classifiers discriminate 
between DLBCL of GCB and Non-GCB type [5, 6].
Nodular lymphocyte predominant Hodgkin 
lymphoma (NLPHL) is a subtype of Hodgkin lymphoma 
(HL). In contrast to classical HL it has several particular 
features, which include a preserved B cell phenotype of 
the tumor cells [7], the LP cells, and a higher frequency 
in males as well as a higher risk of transformation into 
DLBCL. We previously showed in two composite 
lymphoma cases with available frozen tissue the clonal 
relatedness of the NLPHL and DLBCL component [8]. 
These DLBCL transformed from NLPHL (LP-DLBCL) 
often have a sheet-like growth pattern [9]. However, 
among the immunohistochemical markers tested, none of 
them was highly specific for LP-DLBCL [9]. The clinical 
behavior of LP-DLBCL is controversially discussed at 
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the moment. There are data indicating a more aggressive 
course [10], but most studies showed a favorable 
outcome compared to conventional DLBCL [11-15]. 
Therefore, it would be desirable to recognize these cases 
as transformed NLPHL, even when only the DLBCL part 
is biopsied. Recently, we demonstrated that mechanisms 
of transformation from NLPHL into LP-DLBCL can 
be heterogeneous and that in some cases few additional 
mutations may be sufficient for transformation, whereas in 
other cases a huge mutational load together with complex 
chromothripsis-like genomic aberrations are present [8]. 
The aim of the present study was to characterize LP-
DLBCL by gene expression profiling (GEP) to gain further 
insight into its pathogenesis.
RESULTS
Gene expression analysis reveals a strong host 
response signature in LP-DLBCL
Gene expression profiling (GEP) of whole sections 
from 9 formalin-fixed, paraffin-embedded LP-DLBCL 
as well as 20 conventional DLBCL was performed. 
Clinical data of the cases investigated by GEP are listed 
in Supplementary Table S1. Unsupervised hierarchical 
clustering of all 20 conventional DLBCL (11 GCB and 9 
Non-GCB type) and 9 LP-DLBCL cases revealed a core 
group of 7 LP-DLBCL cases, which clustered together. All 
other cases arranged around this core group, without clear 
separation of GCB- or Non-GCB-DLBCL (Figure 1A).
A supervised comparison of LP-DLBCL against 
all other DLBCL cases revealed an overexpression of T 
cell- and macrophage-associated genes (GZMK, MT1H, 
C1QA, CD2, STAT1, CD3D, CD3G, SOD2, Table 1) in 
the LP-DLBCL. Granzyme K (GZMK) is expressed in 
cytotoxic T cells, therefore possibly reflecting a host anti-
lymphoma response. To validate these results, the fraction 
of positive pixels was assessed in immunostained sections, 
in order to automatically quantify the T cell antigen CD3 
and the macrophage antigens C1QA and p-STAT1, which 
were identified to be differentially expressed. Indeed, 
CD3 immunostaining revealed significantly more positive 
pixels in LP-DLBCL cases when compared with GCB 
type DLBCL and Non-GCB type DLBCL, respectively 
(p<0.0001, t-test, Figure 1). Both, C1QA and p-STAT1, 
usually expressed in macrophages, showed higher 
expression values in LP-DLBCL compared with GCB type 
DLBCL (Figure 1, p<0.0001 and p=0.0003, respectively, 
Mann-Whitney-Test). Despite the slightly higher number 
of C1QA-positive pixels in LP-DLBCL compared with 
Non-GCB type DLBCL, the expression of C1QA and 
p-STAT1 was not significantly different in LP-DLBCL 
when compared with Non-GCB type DLBCL.
Several genes known to be expressed in B cells were 
expressed at lower levels in LP-DLBCL than in conventional 
DLBCL, including MS4A1 (CD20), CD24 [16], TCL1A 
[17] and BLNK [18] (Table 2). Downregulation of these B 
cell-specific transcripts indicates either a reduced tumor cell 
content or a partially downregulated B cell phenotype in the 
tumor cells. Since reactive B cells rarely occur among the 
non-neoplastic bystander cells, the fraction of CD20-positive 
pixels reflects the tumor cell content, and was quantified. It 
was significantly lower in LP-DLBCL compared with GCB-
DLBCL (Figure 1E, 1L, 1M, p<0.0001, Mann-Whitney-Test). 
However, the average intensities of CD20-immunostaining 
did not differ between LP-DLBCL and GCB-DLBCL 
(data not shown), arguing against a downregulated B cell 
phenotype in the tumor cells of LP-DLBCL.
Since a prominent, partly cytotoxic host response in 
LP-DLBCL was identified, we compared our GEP data with 
a previous study by Monti et al. [19], in which a subset 
of DLBCL with a strong host inflammatory response was 
detected. When this host response signature was applied 
to the present data set, eight of nine LP-DLBCL clustered 
together (Figure 2A) and showed a significant enrichment of 
this signature using gene set enrichment analysis (p=0.0120, 
Figure 2B), confirming the validity of the present data even 
across different array platforms.
The inflammatory infiltrate in LP-DLBCL shows 
a low CD4/CD8 ratio and a high content of 
macrophages
Since we identified in LP-DLBCL mainly transcripts 
of reactive bystander cells as being differentially expressed 
in comparison to conventional DLBCL, numbers of CD4-
positive and CD8-positive T cells as well as CD163-positive 
macrophages were quantified by the Aperio positive pixel 
count algorithm in these groups (Figure 3). Surprisingly, 
in CD4 immunostaining, a significantly lower number of 
positive pixels was detected in LP-DLBCL when compared 
with DLBCL of the GCB and Non-GCB types (Figure 3A, 
E, F, p=0.0035 and p<0.0001, respectively, Mann-Whitney-
Test). In contrast, LP-DLBCL showed significantly higher 
numbers of CD8-positive pixels when compared with 
both GCB and Non-GCB type DLBCL (Figure 3B, 3G, 
3H p=0.0002 and p=0.0169, respectively, Mann-Whitney-
Test). Also the CD4/CD8 ratio was significantly decreased 
in LP-DLBCL compared with GCB and Non-GCB type 
DLBCL (Figure 3C, p=0.0001 and p=0.0003, respectively, 
Mann-Whitney-Test). CD163 immunostaining confirmed a 
significantly higher amount of macrophages in LP-DLBCL 
compared to GCB and Non-GCB type DLBCL (Figure 
3D, 3I, 3J p<0.0001 and p=0.0003, respectively, Mann-
Whitney-Test).
Host response in vitro reveals a MYC 
downregulation in the tumor cells
Since a strong host response signature was 
observed in GEP of LP-DLBCL, we aimed to simulate 
this situation in vitro by establishing a coculture model 
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Figure 1: Gene expression profiling recognizes LP-DLBCL as a core group among all DLBCL. A. Unsupervised hierarchical 
clustering of gene expression data of LP-DLBCL (red), GCB type DLBCL (yellow) and Non-GCB type DLBCL (blue). We considered 1203 
probe sets with a standard deviation > 2. B. Quantification of the fraction of CD3-positive pixels reveals significantly higher numbers in LP-
DLBCL compared with Non-GCB and GCB DLBCL (***p<0.0001, **p=0.0093 paired t-test). C. Quantification of the fraction of C1QA-
positive pixels reveals significantly higher numbers in LP-DLBCL compared with GCB DLBCL (***p<0.0001, Mann-Whitney-test). 
D. Quantification of the fraction of pSTAT1-positive pixels reveals significantly higher numbers in LP-DLBCL compared with GCB DLBCL 
(***p≤0.0003, Mann-Whitney-test). E. The fraction of CD20-positive pixels was significantly lower in LP-DLBCL compared with GCB 
type DLBCL (***p<0.0001, * p=0.0221, Mann-Whitney-test). F. Representative example of CD3 immunostaining of a LP-DLBCL (200x). 
G. Representative example of CD3 immunostaining of a GCB type DLBCL (200x). H. Representative example of C1QA immunostaining 
of a LP-DLBCL (200x). I. Representative example of C1QA immunostaining of a GCB type DLBCL (200x). J. Representative example of 
pSTAT1 immunostaining of a LP-DLBCL (200x). K. Representative example of pSTAT1 immunostaining of a GCB type DLBCL (200x). 
L. Representative example of CD20 immunostaining of a LP-DLBCL (200x). M. Representative example of CD20 immunostaining of a 
GCB type DLBCL (200x).
Oncotarget72200www.impactjournals.com/oncotarget
of lymphoma cells with T cell and monocyte fractions 
isolated from human peripheral blood mononuclear 
cells (PBMCs). Since no cell line representative for 
LP-DLBCL exists, the DEV cell line, which is the only 
available NLPHL cell line [20, 21], derived from a long 
standing NLPHL, was used. In order to avoid a major 
histocompatibility complex class I or class II (MHC-I or 
MHC-II)-mediated allogeneic anti-tumor reaction [22], 
DEV cells were tested for MHC expression. In line with 
previous studies [23, 24], neither MHC-I nor MHC-II 
expression was detected on DEV cells (Supplementary 
Figure S1). Therefore, MHC-unmatched PBMCs could 
be applied for coculture experiments. MHC expression 
on DEV cells was further monitored during coculture by 
flow cytometry, but remained negative (data not shown). 
The growth behavior of DEV cells was monitored over 
7 days in monoculture or in coculture either with CD3-
positive T cells or CD14-positive monocytes. Under 
both coculture conditions, DEV cells showed a growth 
arrest (Figure 4A). To further elucidate the mechanisms 
involved in growth suppression of DEV cells due to the 
presence of T cells and monocytes, GEP of DEV cells 
purified from 5 days-old cocultures was performed 
in comparison to corresponding monocultures. 
Interestingly, a coculture-induced switch in GEP was 
observed (Figure 4B). The most strongly upregulated 
Table 1: Top 25 genes up regulated in LP-DLBCL compared with conventional DLBCL
Fold 
change
p-value FDR Gene 
Symbol
Gene Description
4.8 0.0014 0.0331 GZMK granzyme K (granzyme 3; tryptase II)
3.4 0.0007 0.0251 GBP1 guanylate binding protein 1, interferon-inducible
3.4 0.0012 0.0322 SMG1 SMG1 phosphatidylinositol 3-kinase-related kinase
3.1 0.0014 0.0331 MT1H metallothionein 1H
3.0 0.0021 0.0409 GBP5 guanylate binding protein 5
3.0 0.0001 0.0086 SLAMF7 SLAM family member 7
2.9 0.0004 0.0180 C1QA complement component 1, q subcomponent, A chain
2.8 0.0015 0.0331 PYHIN1 pyrin and HIN domain family, member 1
2.8 0.0002 0.0143 GIMAP4 GTPase, IMAP family member 4
2.7 0.0008 0.0265 CD2 CD2 molecule
2.6 0.0010 0.0294 GBP2 guanylate binding protein 2, interferon-inducible
2.6 0.0009 0.0278 LCP2 lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 
76kDa)
2.6 0.0046 0.0620 SCARNA8 small Cajal body-specific RNA 8
2.5 0.0003 0.0179 WARS tryptophanyl-tRNA synthetase
2.5 0.0000 0.0086 STOM stomatin
2.5 0.0014 0.0331 SCARNA6 small Cajal body-specific RNA 6
2.5 0.0012 0.0322 STAT1 signal transducer and activator of transcription 1, 91kDa
2.4 0.0005 0.0227 SCARNA10 small Cajal body-specific RNA 10
2.4 0.0000 0.0086 FYN FYN proto-oncogene, Src family tyrosine kinase
2.4 0.0007 0.0251 SNX10 sorting nexin 10
2.3 0.0092 0.0937 CD3D CD3d molecule, delta (CD3-TCR complex)
2.3 0.0039 0.0574 CD3G CD3g molecule, gamma (CD3-TCR complex)
2.3 0.0073 0.0815 SOD2 superoxide dismutase 2, mitochondrial
2.3 0.0003 0.0179 RNF213 ring finger protein 213
2.3 0.0001 0.0101 CST7 cystatin F (leukocystatin)
FDR, false discovery rate
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genes after coculture with either T cells or monocytes 
were HSN2, controlling the transport of sodium and 
chloride ions [25], RAB3A, involved in exocytosis 
[26] and FABP3, regulating fatty acid metabolism 
[27] (Supplementary Table S2). In contrast, the most 
strongly downregulated transcripts were MYC, miR155 
and P2RY14 (Supplementary Table S3). Of note, DEV 
cells isolated from cocultures did not show an enhanced 
expression of T cell or monocyte transcripts, confirming 
a highly efficient depletion of blood cells prior to GEP 
(Supplementary Figures S2 and S3).
Gene set characterization using the Genomatix 
Pathway System revealed several significantly enriched 
pathways, most of them being negatively regulated (Table 
3). Among the top enriched and negatively regulated 
pathways were the E2F transcription factor network, 
validated targets of the MYC transcription factor, the 
MYB transcription factor network as well as cyclins 
and cell cycle regulation. A negative regulation of these 
pathways [28] is consistent with the observed reduced 
proliferation of DEV cells under coculture conditions. 
Downregulation of MYC was also confirmed on transcript 
and protein level in DEV cells after coculture (Figure 4C 
and 4D) and in 12/16 primary LP-DLBCL with > 90% 
MYC-negative tumor cells (Figure 4E). Surprisingly, 
there was no general enrichment of pro-apoptotic genes 
in the pathway analysis (nor in a heat map of pro-
apoptotic genes, Supplementary Figure S4). In contrast, 
DEV cells showed a 2.4-fold upregulation of IL23A after 
coculture experiments, potentially explaining the reduced 
proliferative capacity of DEV cells, since IL23 was shown 
to inhibit cell proliferation of lymphoblastic leukemia cell 
lines in vitro [29].
Inhibition of anti-lymphoma host response 
activation by PD-L1
Although we could not monitor an enhanced 
expression of MHC surface molecules on DEV cells by 
flow cytometry during the coculture experiments, MHC 
class II transcripts were upregulated in GEP (HLA-DRA 
2.3- and HLA-DQB1 2.5-fold), pointing to a possible 
interaction of DEV cells with T cells. Interestingly, DEV 
cells also presented a 2.1-fold upregulation of CD274/PD-
L1 after coculture experiments suggesting an inhibition of 
T cell activation in the coculture. A slight upregulation of 
CD274/PD-L1 was also confirmed on transcript (Figure 
4F) and protein level (Figure 4G). To further investigate 
if this represents a general finding in LP-DLBCL, we 
tested 19 LP-DLBCL cases for PD-L1 expression by 
immunohistochemistry and observed in 12 cases (63%) 
a membrane bound expression in the tumor cells (Figure 
4H). Therefore, PD-L1 was significantly more frequently 
expressed in LP-DLBCL than in DLBCL of the GCB 
type (2/22 cases) and of the Non-GCB type (3/26 cases, 
p<0.0001, Chi-Square-Test). In the PD-L1-negative cases, 
Table 2: Top 15 genes down regulated in LP-DLBCL compared with conventional DLBCL
Fold 
change
p-value FDR Gene Symbol Gene Description
3.3 0.0012 0.0322 CD24 CD24 molecule
3.0 0.0031 0.0519 MT-TL2 mitochondrially encoded tRNA leucine 2 (CUN)
2.9 0.0034 0.0529 RGS13 regulator of G-protein signaling 13
2.8 0.0002 0.0161 RPLP0 ribosomal protein, large, P0
2.7 0.0029 0.0500 MS4A1 membrane-spanning 4-domains, subfamily A, member 1
2.6 0.0000 0.0086 MT-TP mitochondrially encoded tRNA proline
2.4 0.0037 0.0553 TCL1A T-cell leukemia/lymphoma 1A
2.4 0.0011 0.0318 BLNK B-cell linker
2.3 0.0000 0.0086 RPL23A ribosomal protein L23a
2.3 0.0019 0.0387 USMG5 up-regulated during skeletal muscle growth 5 homolog (mouse)
2.3 0.0003 0.0179 RPL12P1 ribosomal protein L12 pseudogene 1
2.2 0.0069 0.0780 C12orf75 chromosome 12 open reading frame 75
2.1 0.0005 0.0228 RPL21 ribosomal protein L21
2.1 0.0003 0.0180 EIF2S3 eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa
2.1 0.0059 0.0700 MT-TM mitochondrially encoded tRNA methionine
FDR, false discovery rate
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PD-L1 expression was mainly restricted to histiocytes in 
the microenvironment.
DISCUSSION
In the present study, GEP of a series of LP-DLBCL 
was performed and revealed a strong inflammatory host 
response, dominated by macrophages and cytotoxic T 
cells. A similar observation was made in a previous study 
by Monti et al. [19], when a large cohort of DLBCL not 
otherwise specified was investigated by GEP and a group 
with a prominent host response reaction was identified. 
In this group, particularly cases with features of T cell/
histiocyte rich large B cell lymphoma (THRLBCL) 
Figure 2: LP-DLBCL is characterized by a strong inflammatory infiltrate. A. Supervised clustering based on the host 
inflammatory response signature identified in THRLBCL [19]. B. Gene set enrichment analysis shows a significant enrichment of the host 
inflammatory response signature [19] in LP-DLBCL compared with all other DLBCL. ES enrichment score, NES normalized enrichment 
score, FDR false discovery rate.
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Figure 3: The inflammatory infiltrate in LP-DLBCL shows a low CD4/CD8 ratio and a high content of macrophages. 
A. The fraction of CD4-positive pixels was significantly lower in LP-DLBCL compared with Non-GCB and GCB type DLBCL 
(***p<0.0001, **p=0.0035, Mann-Whitney-test). B. Quantification of the fraction of CD8-positive pixels reveals significantly higher 
numbers in LP-DLBCL compared with Non-GCB and GCB DLBCL (***p=0.0002, *p=0.0169, Mann-Whitney-test). C. The CD4/
CD8 ratio is significantly decreased in the microenvironment of LP-DLBCL compared with Non-GCB and GCB DLBCL (***p≤0.0003, 
Mann-Whitney-test). D. Quantification of the fraction of CD163-positive pixels reveals significantly higher numbers in LP-DLBCL 
compared with Non-GCB and GCB DLBCL (***p≤0.0003, *p=0.0109, Mann-Whitney-test). E. Representative example of LP-DLBCL 
in CD4 immunostaining (200x). F. Representative example of a GCB type DLBCL in CD4 immunostaining (200x). G. Representative 
example of LP-DLBCL in CD8 immunostaining (200x). H. Representative example of a GCB type DLBCL in CD8 immunostaining 
(200x). I. Representative example of LP-DLBCL in CD163 immunostaining (200x). J. Representative example of a GCB type DLBCL in 
CD163 immunostaining (200x).
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Figure 4: Growth of the NLPHL cell line DEV is impaired in the presence of T cells or monocytes. A. Growth curves of the 
NLPHL cell line DEV in coculture with T cells or monocytes compared to a corresponding monoculture. B. Unsupervised GEP clustering 
of DEV cells in monoculture and DEV cells isolated after 5 days from coculture with T cells or monocytes. Two representative replicates of 
several experiments were analyzed for changes in GEP. We considered 158 probe sets with a standard deviation > 2 for the cluster analysis. 
C. MYC mRNA expression determined by Taqman realtime RT-PCR in DEV cells after coculture with T cells or monocytes, relative to 
GAPDH and relative to DEV cells from monoculture (***p<0.0001, paired t-test). D. Western blot of MYC protein in representative 
samples of DEV cells after coculture with T cells or monocytes compared to a corresponding monoculture. ACTB was used as loading 
control. E. Example of an LP-DLBCL with lack of MYC expression in the majority of the tumor cells (200x). F. CD274/PD-L1 mRNA 
expression determined by Taqman realtime RT-PCR in DEV cells after coculture with T cells or monocytes, relative to GAPDH and relative 
to DEV cells from monoculture (***p<0.0001, paired t-test). G. Western blot of PD-L1 protein in representative samples of DEV cells 
after coculture with T cells or monocytes compared to a corresponding monoculture. ACTB was used as loading control. H. Example of an 
LP-DLBCL with membrane bound CD274/PD-L1 expression in the tumor cells (200x).
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were included. THRLBCL has previously been shown 
to have a large overlap with NLPHL [30-33], but 
usually presents with a more aggressive behavior than 
typical NLPHL, like LP-DLBCL. Although Monti et 
al. investigated a completely different case series and 
also the array platforms differed, seven of the top 25 
genes overexpressed in LP-DLBCL cases in the present 
study, were also identified in the previous host response 
signature. Furthermore, some of the top 25 transcripts 
identified in LP-DLBCL, like MT1H, C1QA, STAT1 
and SOD2, were also shown to be expressed in the 
macrophages of THRLBCL [34, 35], suggesting a similar 
composition of the microenvironment in LP-DLBCL and 
THRLBCL. The strong overlap of microenvironment 
composition in LP-DLBCL and THRLBCL supports a 
close relationship between NLPHL, THRLBCL and LP-
DLBCL, suggesting that THRLBCL might represent 
a transformation of NLPHL with reduced growth of 
the tumor cells and enhanced host response yielding 
a paucicellular pattern. Even in LP-DLBCL we could 
demonstrate a reduced tumor cell content compared with 
conventional DLBCL, however, not reaching below 10% 
as usually observed in THRLBCL [1].
A protective role of high numbers of CD8-positive 
T cells related to improved outcome was observed in 
DLBCL not otherwise specified [36]. It was furthermore 
observed that loss of HLA expression, B7 molecules and 
ICAM1 was associated with decreased infiltration of CD8-
positive T cells in DLBCL [37]. And indeed, consistent 
with the high CD8 content in LP-DLBCL, 100% and 88% 
of cases were tested as positive for ICAM1 and HLA-DR 
expression by immunohistochemistry, respectively (data 
not shown). Likewise, THRLBCL has been described to 
have a relatively high CD8 content [38], which we also 
confirmed in a previous study [32]. THRLBCL may 
therefore represent the extreme form of LP-DLBCL with 
a maximum host response and slow tumor cell growth. 
These findings are somewhat contradictory to the usually 
observed aggressive clinical behavior in THRLBCL [30] 
and in a subset of cases of LP-DLBCL [10].
We also tried to model the prominent T cell- and 
macrophage-rich microenvironment of LP-DLBCL 
using the only available NLPHL cell line DEV [20, 
39]. Despite DEV cells, as all cell lines, have acquired 
independence from their microenvironment, we made the 
observation that growth of DEV cells was hampered by 
the presence of T cells or monocytes, which could explain 
the reduced tumor cell content in LP-DLBCL next to a 
strong inflammatory background. Although we cannot 
exclude that reduced cell numbers of DEV cells after 
coculture were related to an increased rate of apoptosis, 
we could not prove this hypothesis in the data obtained 
from GEP. However, since GEP was performed on day 5, 
cell cycle arrest and growth inhibition may finally result 
in apoptosis at a later time point, suggested by a reduction 
of cell numbers in the growth curve clearly visible at day 
seven following a period of growth stagnation.
Taken together, the coculture conditions may 
represent environmental stress for DEV cells causing 
cell cycle arrest and growth inhibition via MYC 
downregulation. A lack of MYC expression was 
confirmed in the majority of LP-DLBCL tested, whereas 
in conventional DLBCL, around 50% of the cases show 
MYC expression in more than 30% of the tumor cells [40].
Since CD274/PD-L1 was upregulated in DEV cells 
after coculture and in LP-DLBCL biopsies, checkpoint 
Table 3: Top ten enriched canonical signaling pathways according to Genomatix Pathway System in DEV cells after 
coculture with T cells/monocytes
Pathway p-value Upregulated genes Downregulated genes
E2F transcription factor network 0.0005 CDK2, CDKN1A MYC, CCND3, MCM3, 
PRMT5, POLA1
Validated targets of MYC transcription factor 0.0046 - MYC, LDHA, NME1, 
RUVBL1, EIF4G1, DKC1
MYB transcription factor network 0.0059 CDKN1A MYC, MAT2A, SIN3A, MYB, 
HSPA8
Cyclins and cell cycle regulation 0.0093 CDK2, CDKN1A CCND3
Cyclin E destruction pathways 0.0121 CDK2 CUL1
ID 0.0131 CDK2, ID3 ELK3
IL2-beta chain in T cell activation 0.0141 IL2RB MYC, NMI, CCND3
CD28 signalling 0.0141 MAPK8, HLA-DRA, HLA-
DQB1
CD86
E2F1 destruction pathway 0.0150 CDK2 CUL1
IL2 signaling events mediated by STAT5 0.0160 IL2RB MYC, CCND3
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inhibitors could prevent the exhaustion of the relative high 
number of CD8-positive T cells in the microenvironment 
[41] and patients with LP-DLBCL could particularly 
benefit from such therapies. These results are in line with a 
previous study, in which expression of PD-L1 was noted in 
91% of THRLBCL [42]. In contrast, conventional DLBCL 
presented PD-L1 expression only in rare cases in the present 
study, similar to the results reported in a previous study 
[43]. The observation that LP-DLBCL show a high content 
of CD8-positive T cells in most cases and expression of PD-
L1 in the tumor cells is similar to the situation observed in 
other tumors like melanoma, which can basically be divided 
into tumors with and without recruitment of CD8-positive 
T cells [44]. The more mutated neoantigens are expressed 
by a tumor, the more immunogenic appear the tumor cells 
to the host immune system [45, 46]. Hence, several ways 
exist to evade immune system-mediated tumor destruction: 
One way is modulation of cytokine secretion which restricts 
T cell infiltration, another one is immune escape by MHC-
downregulation and a third one, which is likely to be 
responsible for immune escape in LP-DLBCL, is functional 
inhibition of infiltrating CD8-positive T cells by PD-L1- or 
IDO-mediated anergy [47]. In addition to our observation 
of PD-L1 expression in the tumor cells of LP-DLBCL, 
IDO has also been reported to be expressed in macrophages 
and dendritic cells in the microenvironment of THRLBCL 
[35]. Therefore, both LP-DLBCL and THRLBCL present a 
potent host anti-lymphoma reaction, which is functionally 
impaired through immune modulation by the tumor cells.
CONCLUSIONS
In conclusion, we observed a prominent host anti-
lymphoma response in LP-DLBCL, which seems to be 
functionally impaired by PD-L1 expression of the tumor 
cells. Additional MYC downregulation in the tumor 
cells of LP-DLBCL possibly explains the low tumor cell 
content in these cases. Accelerating this ongoing anti-
lymphoma reaction via immune checkpoint inhibitors may 
contribute to an improved survival of these patients.
MATERIALS AND METHODS
Gene expression analysis
Thirty-three primary cases of LP-DLBCL were 
collected in a previous study [9]. As control 11 DLBCL 
classified as GCB type and 9 DLBCL classified as Non-
GCB type (Hans classifier [5]) were included. RNA was 
extracted using the RNeasy FFPE Microkit (Qiagen, 
Hilden, Germany). Since all cases showed partially 
degraded RNA profiles on an Agilent Bioanalyzer 
(Agilent, Waldbronn, Germany), a real time polymerase 
chain reaction (PCR) for GAPDH was performed after 
cDNA synthesis from 766 ng RNA with the High-
capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Darmstadt, Germany). Cases with GAPDH 
Ct values above 30 proved to show insufficient quality 
when hybridized on gene expression arrays. Therefore, 
only cases with GAPDH values below 30 were further 
processed. Nine of the thirty-three LP-DLBCL qualified 
for the study according to their GAPDH values. Of 
these cases, 80 ng RNA were then transcribed using the 
NuGEN Ovation FFPE WTA System (NUGEN, Bemmel, 
The Netherlands). Gene arrays 1.0 (Affymetrix, Santa 
Clara, USA) were hybridized over night according to 
manufacturer’s instructions. Data were analyzed as 
previously described [34]. Gene expression data are 
available through the GEO database (GSE84464). The 
local ethics committee of Frankfurt University Hospital 
agreed on the study (No. 39/14). For gene expression 
analysis of cultured cells, RNA was extracted using the 
RNeasy Mini Kit (Qiagen), amplified with the NUGEN 
Ovation Pico WTA System V2 (NUGEN) and hybridized 
onto Affymetrix Gene arrays 1.0. Gene expression data 
are available through the GEO database (GSE84688). 
Gene set characterization analysis was performed using 
the Genomatix Pathway System (Genomatix, Munich, 
Germany) at default parameters, listing all canonical 
pathways and biological terms with a significant 
enrichment of the provided input genes. Gene set 
enrichment analysis of the host response signature by 
Monti et al. [19] was performed according to http://
software.broadinstitute.org/gsea/index.jsp [48, 49].
Immunohistochemistry, western blot and 
quantitative real time PCR
Genes of interest identified by GEP were validated 
on protein level by immunohistochemistry as described 
previously [50]. Antibodies, providers and dilutions are 
listed in Supplementary Table S4. LP-DLBCL, DLBCL 
classified as GCB type or Non-GCB type (Hans classifier 
[5]), were stained on tissue microarray format. Stained 
slides were scanned using the Aperio Scan Scope XT 
scanner (Aperio, Leica Biosystems, Wetzlar, Germany) 
at 40x magnification. Positivity was evaluated using the 
Aperio Image Scope software and the Aperio Positive 
Pixel Count Algorithm quantifying the positive pixel 
count at default settings. At default settings, the intensity 
limits establish three intensity ranges for classifying and 
summing positive pixel values. In order to avoid a staining 
intensity bias due to fixation artifacts we considered for 
our analysis the sum of all positive pixels (including 
weakly positive, positive and strongly positive pixels). 
Pixels which are stained but do not fall into the positive 
color specification are considered as negative. These pixels 
are counted as well, so that the fraction of all positive 
pixels to total pixels is given.
For comparison of the fraction of positive 
pixels between the groups, the Mann-Whitney-Test 
or t-test was used, depending on the presence of a 
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Gaussian distribution (Shapiro-Wilk-normality test). 
For Western blot analysis, standard conditions were 
applied. Antibodies, providers and dilutions are listed 
in Supplementary Table S4. Western blot images were 
acquired with a Fusion SL (Peqlab, Erlagen, Germany). 
Quantitative real time PCR (rtPCR) was performed on an 
ABI Prism 7900HT Fast Real-Time PCR System (Life 
Technologies, Darmstadt, Germany) using previously 
published primers for GAPDH [51] with Power SYBR 
Green PCR Master Mix (Applied Biosystems). The 
following intron-spanning primers for MYC were 
created: Forward 5´-GCAGCTGCTTAGACGCTGG-3´, 
Reverse 5´-CTCCTCGTCGCAGTAGAAATACG-3’. 
PCR products were sequenced, validating that the correct 
PCR product had been amplified. The cycling program 
consisted of 95°C for 10 min, followed by 40 cycles 
of 95°C for 15 s/60°C for 1 min. Expression of PD-L1 
transcripts was performed using Taqman Universal PCR 
Master Mix and Gene Expression Assays for PD-L1 and 
GAPDH (all Applied Biosystems). Fold changes were 
calculated using the 2-ΔΔCt method.
Functional experiments
The NLPHL cell line DEV was analyzed for 
MHC class I and II expression by flow cytometry using 
specific fluorophore-conjugated antibodies, anti-HLA-
ABC-APC (clone G462.6, BD Pharmingen, Heidelberg, 
Germany), anti-HLA-DR, DP, DQ-FITC (clone Tu39, 
BD Pharmingen). The HL cell line KM-H2 was used as 
positive control. The DEV cell line was cocultured with 
CD3-positive T cells or CD14-positive monocytes isolated 
from PBMCs of healthy donors by Ficoll density gradient 
centrifugation as described previously [22]. Proportions 
of PBMCs were subjected to negative isolation of T 
cells using the Pan T Cell Isolation Kit (Miltenyi Biotec, 
Bergisch-Gladbach, Germany) or positive selection of 
monocytes with CD14 Micro Beads (Miltenyi Biotec). 
Purities of at least 90% were obtained after magnetic cell 
separation (MACS) as it was determined by staining of the 
enriched fractions for CD3 (T cells) or CD14 (monocytes) 
and subsequent flow cytometry analysis.
Tumor cells were cocultured with reactive bystander 
cells in a ratio of 1:10 (2 x 105 lymphoma cells and 2 x 
106 blood cells) in six well plates. Cell numbers were 
determined every two to three days by flow cytometry-
based cell counting from cocultures seeded in triplicates, 
recognizing tumor cells by their unique pattern in forward 
and side scatter (FSC and SSC) and excluding T cells 
and monocytes by staining for surface molecules. The 
cultures were supplied with fresh medium every two to 
three days after cell counting and if required splitted 1:2 
or 1:3 depending on the cell density. For gene expression 
analysis, tumor cells were purified from cocultures at day 
five of coculture by MACS using anti-CD4-, anti-CD8- 
and anti-CD14 Micro Beads (Miltenyi Biotec). Efficient 
removal of blood cell fractions was confirmed by flow 
cytometry analysis obtaining purities of > 94.0% after 
coculture experiments (Supplementary Figure S3).
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